examination, including electrocardiogram and echocardiographic investigation was performed. In the subjects > 50 years of age, bicycle ergometry was performed to exclude asymptomatic heart disease.
Blood samples to measure NT-proBNP and IL-6 were obtained by venipuncture at the time of admission. Blood samples were collected into chilled tubes containing EDTA, immediately placed on ice, and promptly centrifuged (2700 g at 4 °C for 10 minutes). After that plasma was decanted and stored in -20 °C until assayed. Plasma IL-6 levels were measured using the Human IL-6 Immunoassay (Quantikine HS, R&D Systems) and NT-proBNP was measured using the commercially available immunoassay based on sandwich technique ( The data on history, physical examination, echocardiography, laboratory findings, and 28-day follow-up period were prospectively collected for all patients. One-year mortality data were obtained from the registry of our hospital and from the physicians of the patients.
All subjects have given their informed consent. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, and has been approved by The Ethical Committee of our institution.
Statistical analysis
Statistical evaluation was performed with Statistica 5 software. All values are expressed as mean ± SD; the median and range of values are also provided for data with nonnormal distribution. For quantitative data, statistical comparisons were performed using unpaired t tests for normal distributions, and the Wilcoxon test for nonnormal distributions. For qualitative data, χ 2 test was used. The correlations between procedural variables and plasma levels were performed using linear regression analysis and Spearman correlation tests. Survival curves were generated by the means of Kaplan-Meier estimates. To evaluate mortality data, relative risks and 95 percent confidence intervals were calculated as hazard ratios derived from the Cox proportional model. Multiple regression analysis were fitted with the use the clinical covariates. A p value < 0.05 was considered significant.
Results

Clinical characteristics of study population
As shown in Table 1 , the main cause of heart failure was coronary artery disease (82 %).
There was no medication in the control group. Pharmacological treatment of ADHF patients consisted of diuretics in all patients, iv. nitrates in 26 (28 %) pts, and catecholamines were used in 9 (10 %) patients. Pre-discharge medication consisted of betablockers in 54 (58 %) patients, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers in 59 (61 %) patients. Mechanical ventilation was used in 12 (13 %) patients and non-invasive ventilation in 4 (5 %) patients. Aspirin was used in 75 (82 %) patients with coronary artery disease and statins were used in patients with hyperlipidemia.
Plasma IL-6, NT-proBNP levels and clinical characteristics
in patients with ADHF Plasma IL-6 levels were significantly elevated in the patients with ADHF when compared with healthy controls (30.4 ± 22 pg/mL vs. 2.4 ± 1.5 p < 0.01). The median NTproBNP level for all patients was significantly elevated (6 277 pg/mL; interquartile range, 2 639 to 11 562 vs. controls 78 pg/mL; interquartile range, 54 to 110; p < 0.0001). Left ventricle ejection fraction was significantly decreased (34.3 ± 14 % vs. 63.65 ± 5.1 %, p < 0.001).
Significant positive correlation existed between plasma IL-6 and NT-proBNP levels (r = 0.51, p < 0.01, n = 92). The analysis of echocardiography data revealed no significant association between left ventricle ejection fraction (r = -0.09, n = 92).
Relationship between plasma IL-6 level and mortality During 1-year follow-up, 33 of 92 patients (35 %) died. Baseline characteristics associated with one-year mortality are shown in Table 1 . The baseline plasma levels of IL-6 and NT-proBNP were significantly higher in the group of the patients who died during the follow-up, whereas age, gender, diabetes, and ejection fraction were not significantly different in survivors and nonsurvivors.
In order to assess the predictive value of IL-6 in plasma, the patients were divided into subgroups according to quartiles of IL-6. We analyzed clinical variables and mortality rates across the quartiles of IL-6 ( Table 2) . Patients with IL-6 in the upper quartile have had significantly higher plasma NT-proBNP and plasma creatinine level. Mortality rates were increasing across the IL-6 quartiles.
Kaplan-Meier estimates of survival for all subjects according to quartiles of IL-6 are shown in Figure 1 .
Univariate Cox analysis showed that NT-proBNP and IL-6 were significant univariate predictors of mortality. After entering both of these parameters into a multivariate proportional model that included age, sex, creatinine level, ejection fraction, diabetes, smoking, hyperlipidemia, they remained significant independent predictors of mortality (NT-proBNP: p = 0.001; IL-6: p = 0.02).
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Fig. 1:
Overall survival among the patients with acute decompensated heart failure, according to quartiles of IL-6. The IL-6 levels were as follows: first quartile, less than 10.48 pg/mL; second quartile, 10.48 to 27.9 pg/mL; third quartile, 27.9 to 56 pg/mL; and the fourth quartile, more than 56 pg/mL. P < 0.01 by the log rank test for the overall comparison among the groups.
Discussion
This pilot study demonstrates that the increase of IL-6 level in patients with acute decompensated heart failure is associated with NT-proBNP levels and provides prognostic information on mortality from all causes.
Plasma NT-proBNP levels were analyzed in a high number of studies underlying the prognostic importance of NT-proBNP assessment in patients with chronic congestive and acute heart failure (4, 5, 7) .
The assessment of natriuretic peptides has become a good standard for risk stratification and prognosis assessment in patients with acute and chronic heart failure (13, 14) . Little is known about the association of NT-proBNP with cytokines.
Current data support the theory of the contributory role of cytokines (IL-6) in chronic and acute heart failure (14) . Prognostic significance of increased IL-6 levels has been shown in large multicenter studies, but only a few studies focus on IL-6 in acute heart failure.
These studies showed association between increased proinflammatory cytokine levels and increased mortality (4, 12) .
In our study, we demonstrate the prognostic significance of increased plasma IL-6 level. This statement is supported by the following facts: first, the baseline levels of IL-6 were significantly higher in nonsurvivors than in survivors; second, Kaplan-Meier analyses showed that patients' survival decreased as a function of increasing levels of interleukin 6; third, multivariate Cox proportional model showed that circulating IL-6 level was the significant independent predictor of mortality.
Our study demonstrates the association between plasma IL-6 and NT-proBNP levels. Plasma NT-proBNP levels were also significantly increased in nonsurvivors compared to survivors. Also, Cox regression model showed that plasma NT-proBNP level remained the independent prognostic factor.
Association between interleukin 6 and NT-proBNP were demonstrated by the linear regression analysis, correlation coefficient and increasing value of NT-proBNP in IL-6 quartiles.
Conclusions
Plasma interleukin 6 levels provide novel and prognostic information in the patients with ADHF. Combining measurements of interleukin 6 and NT-proBNP seem to be a promising tool in the prognostic assessment of these patients.
